Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05338658 | Study of PAT in Patients With Solid Tumor Cancers | recruiting | Phase 1 | 21 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06241456 | FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | recruiting | Phase 1 | 351 | Fate TherapeuticsINDUSTRY | 1 | Dec 9, 2025 | clinicaltrials |
| NCT06735144 |
| Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors |
| recruiting |
| Phase 1 / Phase 2 |
| 200 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Dec 5, 2025 |
| clinicaltrials |
| NCT07265921 | A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors(Solid Tumors) | recruiting | Phase 1 | 232 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04151342 | CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)(CARMA-BROS) | recruiting | — | 5,500 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Pasithea Therapeutics Corp.INDUSTRY | 3 | Dec 3, 2025 | clinicaltrials |
| NCT06703177 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 876 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06925581 | A Trial of HRS-6768 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 84 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.(BOREALIS-1) | recruiting | Phase 1 | 200 | Erasca, Inc.INDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07249060 | Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients(INTER-AUTENTIC) | recruiting | — | 300 | Hospital Universitario ArabaOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06840821 | Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors | recruiting | Phase 1 / Phase 2 | 156 | Mainline Biosciences (Shanghai) Co., LtdOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259889 | Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors | recruiting | Phase 1 | 13 | Guangzhou Xiling Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06439888 | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer(LySATRA) | recruiting | Phase 1 / Phase 2 | 58 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07208136 | A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors | recruiting | Phase 1 | 102 | JemincareINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256782 | A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 444 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors | recruiting | Phase 1 / Phase 2 | 312 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05547321 | Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. | recruiting | Phase 1 | 150 | Oncomatryx Biopharma S.L.INDUSTRY | 2 | Nov 25, 2025 | clinicaltrials |
| NCT06478251 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | TingBo LiangOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06484790 | T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor | recruiting | Phase 1 | 9 | Ting DengOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07083323 | A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 262 | Sichuan Huiyu Pharmaceutical Co., LtdINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06238401 | An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 77 | Hangzhou Adcoris Biopharmacy Co., LtdINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06988475 | DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05914116 | A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 862 | DualityBio Inc.INDUSTRY | 4 | Nov 21, 2025 | clinicaltrials |
| NCT04299191 | Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 28 | Laminar PharmaceuticalsINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05522868 | SB17170 Phase 1 Clinical Trial in Solid Tumors | recruiting | Phase 1 | 50 | SPARK BiopharmaINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05585684 | Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection | recruiting | — | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06184035 | A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer(Tumorad) | recruiting | Phase 1 / Phase 2 | 90 | Spago Nanomedical ABINDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06500676 | A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 407 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07071103 | Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors(ILDR-02) | recruiting | Phase 2 | 48 | Chuangzhen ChenOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07240207 | Dissecting Tumour MicroenvirOnment in Solid Paediatric Tumour to Improve Adoptive Cell Therapy(MOST) | recruiting | — | 44 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07123415 | A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 110 | Aptabio Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT03572192 | Tissue Collection Framework To Improve Outcomes In Solid Tumours | recruiting | — | 3,000 | Queen Mary University of LondonOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04510766 | Tumor Molecular Profiling in Early Phase Clinical Trials | recruiting | — | 40 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04999384 | First in Human, Dose Escalation Study of AN4005 | recruiting | Phase 1 | 31 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Nov 18, 2025 | clinicaltrials |
| NCT07126665 | A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 116 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07130383 | A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors | recruiting | Phase 2 | 210 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06258408 | A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 78 | Broadenbio Ltd., Co.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06618651 | A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 162 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07229898 | A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 48 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07231081 | Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 85 | Tcelltech Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05661461 | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | recruiting | Phase 1 | 28 | Aadi Bioscience, Inc.INDUSTRY | 1 | Nov 13, 2025 | clinicaltrials |
| NCT01050296 | Molecular Analysis Of Solid Tumors(MAST) | recruiting | — | 1,000 | St. Jude Children's Research HospitalOTHER | 1 | Nov 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2025source: clinicaltrials